What is Compugen's earnings per share (EPS)?

Compugen (CGEN) reported diluted earnings per share of $0.38 for fiscal year 2025. This represents a 337.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Compugen Financials

CGEN

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows Compugen (CGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CGEN FY2025 2026-04-22

Revenue scale finally cleared the fixed R&D base, turning an asset-light research model from burn into cash generation.

Over two years, operating results swung from -$13.0M to $31.3M even as R&D and SG&A moved lower, which points to fixed-cost absorption rather than a one-time cut. Cash conversion also strengthened because operating cash flow of $31.6M nearly matched net income while capex was only $306K, so the turnaround did not require heavy reinvestment.

Liquidity now looks materially stronger: cash of $90.6M sits above total liabilities, and equity recovered to $102.7M, giving the balance sheet a more defensive posture. That matters because retained earnings are still -$453.4M and the current ratio of 6.6x means current strength comes from present liquidity, not from years of retained profits.

The margin shape says more than the revenue line: gross margin rebounded to 87.3% from 71.5%, but the bigger shift is that R&D and SG&A now leave room for profit instead of swallowing gross profit. With free cash flow margin at 43.1%, the model currently behaves like a far less capital-hungry business than its earlier loss phase suggested.

Financial Health Signals

Financial Health Score 82/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Compugen's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

0.46

Compugen scores 0.46, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($217.5M) relative to total liabilities ($53.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Compugen passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.90x

For every $1 of reported earnings, Compugen generates $0.90 in operating cash flow ($31.6M OCF vs $35.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

1118.8x

Compugen earns $1118.8 in operating income for every $1 of interest expense ($31.3M vs $28K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$72.8M

YoY+161.1%

5Y CAGR+105.2%

10Y CAGR+22.9%

Compugen generated $72.8M in revenue in fiscal year 2025. This represents an increase of 161.1% from the prior year.

EBITDA

$31.8M

YoY+320.8%

Compugen's EBITDA was $31.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 320.8% from the prior year.

Net Income

$35.3M

YoY+348.4%

Compugen reported $35.3M in net income in fiscal year 2025. This represents an increase of 348.4% from the prior year.

EPS (Diluted)

$0.38

YoY+337.5%

Compugen earned $0.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 337.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$31.3M

YoY-36.7%

Compugen generated $31.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 36.7% from the prior year.

Cash & Debt

$90.6M

YoY+397.0%

5Y CAGR+66.2%

10Y CAGR+23.7%

Compugen held $90.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

95M

YoY+5.6%

5Y CAGR+2.5%

10Y CAGR+6.5%

Compugen had 95M shares outstanding in fiscal year 2025. This represents an increase of 5.6% from the prior year.

Margins & Returns

Gross Margin

87.3%

YoY+15.7pp

5Y CAGR-9.7pp

10Y CAGR+4.9pp

Compugen's gross margin was 87.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 15.7 percentage points from the prior year.

Operating Margin

43.0%

YoY+96.5pp

5Y CAGR+1617.8pp

10Y CAGR+268.5pp

Compugen's operating margin was 43.0% in fiscal year 2025, reflecting core business profitability. This is up 96.5 percentage points from the prior year.

Net Margin

48.6%

YoY+99.6pp

5Y CAGR+1533.5pp

10Y CAGR+265.9pp

Compugen's net profit margin was 48.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 99.6 percentage points from the prior year.

Return on Equity

34.4%

YoY+60.3pp

5Y CAGR+59.2pp

10Y CAGR+56.8pp

Compugen's ROE was 34.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 60.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$22.8M

YoY-8.3%

5Y CAGR-0.0%

10Y CAGR+0.7%

Compugen invested $22.8M in research and development in fiscal year 2025. This represents a decrease of 8.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$306K

YoY+159.3%

5Y CAGR+13.0%

10Y CAGR-20.7%

Compugen invested $306K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 159.3% from the prior year.

CGEN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$72.8M+161.1%	$27.9M-16.7%	$33.5M+346.1%	$7.5M+25.0%	$6.0M+200.0%	$2.0M
Cost of Revenue	$9.3M+16.7%	$7.9M+295.7%	$2.0M+105.5%	$975K+43.4%	$680K+1033.3%	$60K
Gross Profit	$63.5M+218.6%	$19.9M-36.6%	$31.5M+382.1%	$6.5M+22.7%	$5.3M+174.2%	$1.9M
R&D Expenses	$22.8M-8.3%	$24.8M-28.0%	$34.5M+12.5%	$30.6M+6.8%	$28.7M+26.1%	$22.8M
SG&A Expenses	$8.9M-5.8%	$9.4M-3.0%	$9.7M-5.7%	$10.3M-5.0%	$10.9M+10.7%	$9.8M
Operating Income	$31.3M+310.4%	-$14.9M-14.6%	-$13.0M+63.3%	-$35.4M-0.9%	-$35.1M-11.4%	-$31.5M
Interest Expense	$28K-17.6%	$34K+9.7%	$31K+14.8%	$27K+8.0%	$25K-40.5%	$42K
Income Tax	$54K-98.8%	$4.5M-49.6%	$9.0M+15365.5%	$58K	$0	$0
Net Income	$35.3M+348.4%	-$14.2M+24.1%	-$18.8M+44.3%	-$33.7M+1.5%	-$34.2M-15.2%	-$29.7M
EPS (Diluted)	$0.38+337.5%	$-0.16+23.8%	$-0.21+46.2%	$-0.39+4.9%	$-0.41-10.8%	$-0.37

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CGEN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$156.6M+36.2%	$115.0M-5.2%	$121.3M+28.8%	$94.2M-28.7%	$132.2M-4.4%	$138.3M
Current Assets	$148.0M+39.6%	$106.0M-7.5%	$114.6M+33.0%	$86.1M-30.1%	$123.2M-4.5%	$129.1M
Cash & Equivalents	$90.6M+397.0%	$18.2M+31.2%	$13.9M+25.6%	$11.1M+41.8%	$7.8M+9.2%	$7.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$61.0M	N/A	N/A	$2.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$53.8M-10.4%	$60.1M+7.7%	$55.8M+238.1%	$16.5M-35.2%	$25.5M+37.4%	$18.5M
Current Liabilities	$22.6M+12.0%	$20.2M-23.2%	$26.3M+120.4%	$11.9M-30.3%	$17.1M+62.5%	$10.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$102.7M+87.1%	$54.9M-16.2%	$65.6M-15.6%	$77.7M-27.2%	$106.7M-10.9%	$119.8M
Retained Earnings	-$453.4M+7.2%	-$488.8M-3.0%	-$474.5M-4.1%	-$455.8M-8.0%	-$422.1M-8.8%	-$387.9M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$156.6M+47.0%	$106.5M-7.4%	$115.0M+4.4%	$110.2M-9.2%	$121.3M+57.5%	$77.1M-18.2%	$94.2M-14.6%	$110.3M
Current Assets	$148.0M+51.6%	$97.6M-7.9%	$106.0M+3.8%	$102.1M-10.9%	$114.6M+65.1%	$69.4M-19.4%	$86.1M-15.6%	$102.0M
Cash & Equivalents	$90.6M+1300.9%	$6.5M-64.5%	$18.2M+53.5%	$11.9M-14.5%	$13.9M-18.6%	$17.1M+54.4%	$11.1M+38.1%	$8.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$5.0M-91.8%	$61.0M	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$53.8M-4.3%	$56.3M-6.3%	$60.1M+15.9%	$51.8M-7.1%	$55.8M+270.5%	$15.1M-8.7%	$16.5M-17.2%	$19.9M
Current Liabilities	$22.6M+9.7%	$20.6M+2.1%	$20.2M-18.6%	$24.8M-5.7%	$26.3M+143.2%	$10.8M-9.4%	$11.9M-14.8%	$14.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$102.7M+104.4%	$50.3M-8.5%	$54.9M-5.9%	$58.3M-11.0%	$65.6M+5.7%	$62.0M-20.2%	$77.7M-14.1%	$90.4M
Retained Earnings	-$453.4M+9.9%	-$503.3M-3.0%	-$488.8M-1.0%	-$483.9M-2.0%	-$474.5M0.0%	-$474.4M-4.1%	-$455.8M-3.4%	-$440.9M

CGEN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$31.6M-36.2%	$49.6M+238.2%	-$35.9M-5.2%	-$34.1M-50.3%	-$22.7M+19.9%	-$28.3M
Capital Expenditures	$306K+159.3%	$118K-31.4%	$172K-63.9%	$477K+63.4%	$292K+75.9%	$166K
Free Cash Flow	$31.3M-36.7%	$49.5M+237.2%	-$36.1M-4.2%	-$34.6M-50.5%	-$23.0M+19.3%	-$28.5M
Investing Cash Flow	$30.0M+164.9%	-$46.3M-230.3%	$35.5M-4.2%	$37.1M+460.2%	$6.6M+108.1%	-$82.2M
Financing Cash Flow	$10.6M+1814.1%	$554K-82.0%	$3.1M+772.8%	$353K-97.9%	$16.8M-84.5%	$108.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CGEN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	87.3%+15.7pp	71.5%-22.5pp	94.0%+7.0pp	87.0%-1.7pp	88.7%-8.3pp	97.0%
Operating Margin	43.0%+96.5pp	-53.4%-14.6pp	-38.8%+432.8pp	-471.6%+112.9pp	-584.6%+990.2pp	-1574.8%
Net Margin	48.6%+99.6pp	-51.1%+5.0pp	-56.0%+393.2pp	-449.3%+120.8pp	-570.0%+914.9pp	-1484.9%
Return on Equity	34.4%+60.3pp	-25.9%+2.7pp	-28.6%+14.8pp	-43.4%-11.3pp	-32.1%-7.3pp	-24.8%
Return on Assets	22.6%+35.0pp	-12.4%+3.1pp	-15.5%+20.3pp	-35.8%-9.9pp	-25.9%-4.4pp	-21.5%
Current Ratio	6.56+1.3	5.26+0.9	4.36-2.9	7.23+0.0	7.21-5.1	12.27
Debt-to-Equity	0.52-0.6	1.09+0.2	0.85+0.6	0.21-0.0	0.24+0.1	0.15
FCF Margin	43.0%-134.5pp	177.6%+285.4pp	-107.8%+353.4pp	-461.2%-78.2pp	-383.0%+1041.3pp	-1424.3%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	6.56+1.8	4.74-0.5	5.26+1.1	4.12-0.2	4.36-2.1	6.43-0.8	7.23-0.1	7.29
Debt-to-Equity	0.52-0.6	1.12+0.0	1.09+0.2	0.89+0.0	0.85+0.6	0.24+0.0	0.210.0	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Io Biotech, Inc. IOBT

$3.5M

Avalo Therapeutics Inc AVTX

$994.0M

Inovio Pharmaceu INO

$95.4M

MOLECULAR PARTNERS AG MOLN

$150.4M

Genelux Corp GNLX

$132.7M

Frequently Asked Questions

What is Compugen's annual revenue?

Compugen (CGEN) reported $72.8M in total revenue for fiscal year 2025. This represents a 161.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Compugen's revenue growing?

Compugen (CGEN) revenue grew by 161.1% year-over-year, from $27.9M to $72.8M in fiscal year 2025.

Is Compugen profitable?

Yes, Compugen (CGEN) reported a net income of $35.3M in fiscal year 2025, with a net profit margin of 48.6%.

What is Compugen's EBITDA?

Compugen (CGEN) had EBITDA of $31.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Compugen's gross margin?

Compugen (CGEN) had a gross margin of 87.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Compugen's operating margin?

Compugen (CGEN) had an operating margin of 43.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Compugen's net profit margin?

Compugen (CGEN) had a net profit margin of 48.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Compugen's return on equity (ROE)?

Compugen (CGEN) has a return on equity of 34.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Compugen's free cash flow?

Compugen (CGEN) generated $31.3M in free cash flow during fiscal year 2025. This represents a -36.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Compugen's operating cash flow?

Compugen (CGEN) generated $31.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Compugen's total assets?

Compugen (CGEN) had $156.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Compugen's capital expenditures?

Compugen (CGEN) invested $306K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Compugen spend on research and development?

Compugen (CGEN) invested $22.8M in research and development during fiscal year 2025.

How many shares does Compugen have outstanding?

Compugen (CGEN) had 95M shares outstanding as of fiscal year 2025.

What is Compugen's current ratio?

Compugen (CGEN) had a current ratio of 6.56 as of fiscal year 2025, which is generally considered healthy.

What is Compugen's debt-to-equity ratio?

Compugen (CGEN) had a debt-to-equity ratio of 0.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Compugen's return on assets (ROA)?

Compugen (CGEN) had a return on assets of 22.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Compugen's Altman Z-Score?

Compugen (CGEN) has an Altman Z-Score of 0.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Compugen's Piotroski F-Score?

Compugen (CGEN) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Compugen's earnings high quality?

Compugen (CGEN) has an earnings quality ratio of 0.90x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Compugen cover its interest payments?

Compugen (CGEN) has an interest coverage ratio of 1118.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Compugen?

Compugen (CGEN) scores 82 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.